CatalystMarker
← board

BHST

distress 3/10 · well-funded / low risk
$2.18-4%today-83% from 52w high
bioharvest.com89 employeesVancouver, BCPackaged Foods
Revenue
$35M
Liquidity
$23M
Runway
3.2 yrs
Shares 1y
0%

Price & events

-62.2% over 6M
$2.18$3.98$5.77Jan 26Apr 26Jul 26169krating: Roth Capital: Buy (2026-02-19)
CatalystRating changeDilutionFinancingdashed = today
-4.4%
1D
-23.5%
1W
-28.5%
1M
-50.5%
3M
-62.2%
6M
-68.4%
1Y
-63.5%
2Y
-81.1%
5Y
-78.5%
All

Overview

Market Cap
$49.41M
Volume
94.40K
52 Week Range
$2.18 – $12.65
Total Shares
22.67M
Float Shares
19.32M
Short %
0.37%
% Held by Insiders
14.77%
% Held by Institutions
7.80%
RVOL
2.83x
Beta
1.38

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 22,666,842 · 4 offerings/1y · 0 PIPEs
  • 2025-11-10424B5offering
  • 2025-11-06424B7offering
  • 2025-10-15424B7offering
  • 2025-09-24424B7offering
  • 2025-09-08EFFECTshelf_effective
  • 2025-08-28F-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-02-19Roth CapitalBuy
  • 2025-04-08HC Wainwright & Co.Buy
  • 2024-12-18Maxim GroupBuy
  • 2024-12-11HC Wainwright & Co.Buy
  • 2024-12-06HC Wainwright & Co.Buy

Competitors

  • none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.